Post
Servier’s Phase III INDIGO trial of vorasidenib meets endpoints
Servier has reported that the Phase III INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 isocitrate …
AstraZeneca reports positive results from ADAURA Phase III trial
AstraZeneca has reported positive results from the ADAURA Phase III trial of Tagrisso (osimertinib) in the adjuvant treatment of patients …
Vivavision’s Phase IIa study of ophthalmic solution meets primary endpoints
Vivavision Biotech has reported that its Phase IIa first in human study of VVN539 Ophthalmic Solution in the US has met …
Chimeric launches Phase IB trial of glioblastoma multiforme therapy
Chimeric Therapeutics has launched a new Phase IB clinical trial of CHM 1101 (CLXT CAR T) cell therapy to treat …
Elicio reports positive interim clinical data of cancer immunotherapy study
Elicio Therapeutics has reported positive interim clinical data from its ongoing Phase I AMPLIFY-201 study evaluating its cancer immunotherapy, ELI-002, …
BioInvent receives IND approval for study of anti-TNFR2 antibody
BioInvent International has received investigational new drug (IND) approval to initiate a Phase I/IIa study of BI-1910. Compared to BioInvent’s BI-1808 …
Leading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, …
First patient enrolled in pulmonary hypertension reduction device study
Paris-based Gradient Denervation Technologies has performed the first procedure in its first-in-human clinical study for a pulmonary hypertension device. The …
Innovent and Merck to carry out cancer combination therapy trial
Innovent Biologics and Merck have entered a clinical trial collaboration and supply agreement for the combination therapy of IBI351 (GFH925) …
YS Biopharma receives approval for vaccine trial in Philippines
The Food and Drug Administration (FDA) of the Philippines has given approval to biopharmaceutical firm YS Biopharma to begin a …
Bluejay Therapeutics makes progress in Hepatitis B and D Trials
Bluejay Therapeutics has reported the successful completion of a Phase Ia trial and enrolment of the initial Phase Ib cohorts …
AstraZeneca abandons inflammatory bowel disease drug
AstraZeneca’s brazikumab inflammatory bowel disease (IBD) development programme has been discontinued due to trial delays. Brazikumab, an anti-IL-23 monoclonal antibody, was …
Athersys begins enrolment in final cohort of MultiStem trial
US-based biotechnology company Athersys has begun enrolling patients in the third and final cohort of a Phase II study of …
Sirnaomics doses first patient in anticoagulant treatment trial
US-based biopharmaceutical company Sirnaomics has dosed the first patient in a Phase I clinical trial of STP122G, an RNAi drug …
Saudi astronaut concludes space experiments on inflammatory diseases
Saudi Arabia’s astronaut Rayyanah Barnawi has completed the implementation of King Faisal Specialist Hospital and Research Center (KFSH&RC) cell science …